having stock ownership in Eli Lilly, Gilead Sciences, and Pfizer; being the founder of Oncobox Device, Inc.; and having issued patents for a lymph node specimen collection kit. The remaining authors declare no conflict of interest.
ablation site recurrence, three were successfully retreated (primary efficacy rate 76%; assisted efficacy rate 85%). Median disease free survival was 4.5 months (95%-CI 2.8-6.1 months); first site of disease recurrence was liver (n ¼ 11), lung (n ¼ 3), liver & lung (n ¼ 11), intestines (n ¼ 2), peritoneal deposits (n ¼ 3), bone (n ¼ 2), and brain (n ¼ 1). Median overall survival was not reached; one-year overall survival was 78%. Conclusions: IRE represents a safe and effective technique for patients with small CRLM (3.5 cm) that are unsuitable for surgery and thermal ablation. Although the outcome regarding local tumor control appears to be promising, the relatively high number of early distant site recurrences should keep us wary. The results mandate the setup of a trial comparing IRE to stereotactic ablative radiotherapy (SABR) for CRLM unsuitable for surgery and thermal ablation (COLDFIRE-3).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.